FFR CT : Clinical studies



Similar documents
For the NXT Investigators

Non-invasive FFR Using Coronary CT Angiography and Computational Fluid Dynamics Predicts the Hemodynamic Significance of Coronary Lesions

Non-invasive functional testing in 2014

MYOCARDIAL PERFUSION COMPUTED TOMOGRAPHY PhD course in Medical Imaging. Anne Günther Department of Radiology OUS Rikshospitalet

Main Effect of Screening for Coronary Artery Disease Using CT

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

Efficient Evaluation of Chest Pain

Majestic Trial 12 Month Results

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Perioperative Cardiac Evaluation

The Bioresorbable Vascular Stent Dr Albert Ko

Cilostazol versus Clopidogrel after Coronary Stenting

Prognostic impact of uric acid in patients with stable coronary artery disease

LEADERS: 5-Year Follow-up

Renovascular Hypertension

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

on behalf of the AUGMENT-HF Investigators

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

06 Validation of risk prediction model

EMR Tutorial Acute Coronary Syndrome

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

Listen to your heart: Good Cardiovascular Health for Life

CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD

Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm. Invasiv tryckmätning FFR

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

PCI vs. CABG for Left Main Disease

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

Will The Coronary Calcium Score Affect the Decision To Treat With Statins?

Antonio Colombo MD on behalf of the SECURITY Investigators

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Section 8: Clinical Exercise Testing. a maximal GXT?

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

Predictive Implications of Stress Testing (Chapt. 14) 1979, Weiner and coworkers. Factors to improve the accuracy of stress testing

Q1: Global risk assessment using PROCAM, SCORE, FRAMINGHAM or REYNOLDS ecc is sufficient YES NO NEED MORE DATA DISCUSS within Taskforce Your Comments

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Evaluation of Predictive Models

All patients presenting to the Emergency Department with symptoms suggestive of

Low-dose CT for Pulmonary Embolism

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators

Utilizing the Cath Lab for Cardiac Arrest

Remote Delivery of Cardiac Rehabilitation

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

Evaluation of Diagnostic and Screening Tests: Validity and Reliability. Sukon Kanchanaraksa, PhD Johns Hopkins University

R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney,

California Health and Safety Code, Section

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Adult Cardiology. Diagnosis of Arterial Disease of the Lower Extremities With Duplex Scanning: A Validation Study

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up

MEDICAL POLICY No R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Addendum to Clinical Review for NDA

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

scan: : a new tool to analyse

Antiplatelet and Antithrombotics From clinical trials to guidelines

Atherosclerosis of the aorta. Artur Evangelista

Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources

New Approaches to, and Indications for, Antiplatelet Therapy

Diagnostic and Therapeutic Procedures

Clinical Study Synopsis

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Press. Siemens solutions support diagnosis and treatment of cardiovascular diseases

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

ADenosine Vasodilator Independent Stenosis Evaluation II

38 year old female with mild obesity. She is planning an exercise program to loose weight. She has no other known risk factors for CAD.

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Chest Pain. Acute Myocardial Infarction: Differential Diagnosis and Patient Management. Common complaint in ED. Wide range of etiologies

Transcription:

FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens

Coronary CTA: High diagnostic sensitivity for detecting CAD, and the best non-invasive test for ruling-out CAD BUT!! Cheng V et al, JACC Imag. 2008 Meijboom W et al, JACC 2008 Schuijj JD et al JACC 2006

Coronary CTA: High diagnostic sensitivity for detecting CAD, and the best noninvasive test for ruling-out CAD BUT!! Poor correlation to stenosis severity as assessed with ICA Cheng V et al, JACC Imag. 2008 Meijboom W et al, JACC 2008 Schuijj JD et al JACC 2006

Coronary CTA: High diagnostic sensitivity for detecting CAD, and the best noninvasive test for ruling-out CAD BUT!! Poor correlation to stenosis severity as assessed with ICA The hemodynamic significance of a stenosis cannot be assessed Cheng V et al, JACC Imag. 2008 Meijboom W et al, JACC 2008 Schuijj JD et al JACC 2006

FFR CT : Clinical studies PET-CT eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee FFR CT eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeemmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmeeeeeee eeeeeeeeeeeeeeee Image source Gaemperli O, EHJ 2011

FFR CT : Clinical studies PET-CT CT-perfusion eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee FFR CT eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeemmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmeeeeeee eeeeeeeeeeeeeeee Image source Gaemperli O, EHJ 2011

FFR CT : Clinical studies PET-CT CT-perfusion eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee FFR eeeeeeeeeeeeeeeeeeeeeee CT FFR CT eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeeeeeeeeeeeee eeeeeeeeeeeemmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmmmmm mmmmmmmmmmeeeeeee eeeeeeeeeeeeeeee Image source Gaemperli O, EHJ 2011

FFR CT : Clinical studies DISCOVER-FLOW Completed 2011 N=104 patients DeFACTO Completed 2012 N=252 patients NXT Completed 2013 N~254 patients

FFR CT : Clinical studies, DISCOVER-FLOW trial 4 centers Patients with suspected or known CAD who underwent ccta, ICA and FFR Koo B-K, JACC 2011

FFR CT : Clinical studies, DISCOVER-FLOW trial 4 centers Patients with suspected or known CAD who underwent ccta, ICA and FFR Significant CAD by ccta: stenosis >50% (>2 mm vessel) Ischemia def: FFR CT / FFR 0.80 FFR CT and ccta core lab reads, FFR local reads Koo B-K, JACC 2011

FFR CT : Clinical studies, DISCOVER-FLOW trial 4 centers Patients with suspected or known CAD who underwent ccta, ICA and FFR Significant CAD by ccta: stenosis >50% (>2 mm vessel) Ischemia def: FFR CT / FFR 0.80 FFR CT and ccta core lab reads, FFR local reads 104 patients, 159 vessels Mean age, 63 y, 20% with known disease (AMI / PCI), 56% with FFR 0.80 Koo B-K, JACC 2011

FFR CT : Clinical studies, DISCOVER-FLOW trial Koo B-K, JACC 2011

FFR CT : Clinical studies, DISCOVER-FLOW trial P=0.001 P=0.0001 Koo B-K, JACC 2011

FFR CT : Clinical studies, DeFACTO trial 17 centers Clinically non-emergent indicated ICA after ccta <60 days ICA stenosis 30%-90% (>2 mm vessel) % Min J et al, JAMA 2012

FFR CT : Clinical studies, DeFACTO trial 17 centers Clinically non-emergent indicated ICA after ccta <60 days ICA stenosis 30%-90% (>2 mm vessel) Significant CAD by ccta: stenosis >50% (>2 mm vessel) Ischemia def: FFR CT / FFR 0.80 % Min J et al, JAMA 2012

FFR CT : Clinical studies, DeFACTO trial 17 centers Clinically non-emergent indicated ICA after ccta <60 days ICA stenosis 30%-90% (>2 mm vessel) Significant CAD by ccta: stenosis >50% (>2 mm vessel) Ischemia def: FFR CT / FFR 0.80 % FFR CT and ccta core lab reads, FFR local reads Min J et al, JAMA 2012

FFR CT : Clinical studies, DeFACTO trial 17 centers Clinically non-emergent indicated ICA after ccta <60 days ICA stenosis 30%-90% (>2 mm vessel) Significant CAD by ccta: stenosis >50% (>2 mm vessel) Ischemia def: ccta stenosis >50%, FFR CT / FFR 0.80 % FFR CT and ccta core lab reads, FFR local reads Primary study end-point: Per-patient diagnostic accuracy of FFR CT for the diagnosis of ischemia with a lower limit of 95% CI >70% Min J et al, JAMA 2012

FFR CT : Clinical studies, DeFACTO trial Min J et al, JAMA 2012 252 patients, 406 vessels Patient Characteristics Age (years) [mean + SD] 63 ± 9 Male gender 71% Prior MI 6% Prior PCI 6% Hypertension 71% Diabetes mellitus 22% Agatston score [mean + SD] 382 ± 401 FFR 0.80 37%

FFR CT : Clinical studies, DeFACTO trial Min J et al, JAMA 2012 Primary end point 100 90 80 70 60 73 73 64 64 90 84 54 54 67 61 84 FFR CT <0.80 ccta >50% 72 50 40 42 42 30 20 10 0 95% CI FFR CT ccta Accuracy Sensitivity Specificity PPV NPV 67-78 58-70 84-95 77-90 46-83 34-51 60-74 53-67 74-90 61-81

FFR CT : Clinical studies, DeFACTO trial Min J et al, JAMA 2012 % AUC, 0.68 (0.62-0.74) vs 0.81 (0.75-0.86) p<0.0001

FFR CT : Clinical studies, DeFACTO vs NXT trial design Gaur S et al, JCCT 2013

FFR CT : Clinical studies, DeFACTO vs NXT trial design Gaur S et al, JCCT 2013

FFR CT : Clinical studies, DeFACTO vs NXT trial design Gaur S et al, JCCT 2013

FFR CT : Clinical studies, DeFACTO vs NXT trial design Gaur S et al, JCCT 2013

Abbara S et al. JCCT 2009 FFR CT : Clinical studies, NXT trial, Study objectives To determine the diagnostic performance of non-invasive FFR CT using FFR as the reference standard To compare the diagnostic performance of FFR CT vs. anatomic testing (coronary CTA or invasive coronary angiography)

FFR CT : Clinical studies, NXT trial, Patient recruitment Inclusion Criteria: Underwent >64-row CT and ICA scheduled < 60 days between CT and ICA Exclusion Criteria: Prior CABG or PCI Suspected ACS Recent MI within 30 days of CT Contraindication to nitrates, beta blockade or adenosine ICA = Invasive coronary angiography; CABG = coronary artery bypass surgery; ACS = acute coronary syndrome; MI = myocardial infarction; PCI = percutaneous coronary intervention

FFR CT : Clinical studies, NXT trial, Endpoints Primary Endpoint: Per-patient diagnostic performance as assessed by the area under the receiver operating characteristic curve (AUC) of FFR CT vs. coronary CTA for the diagnosis of ischemia in patients with stenosis severity 30%-90% (vessel diameter >2 mm) Secondary Endpoint: Diagnostic performance (accuracy, sensitivity, specificity, PPV and NPV) of FFR CT, coronary CTA, and invasive coronary angiography

FFR CT : Clinical studies, NXT trial, Study procedures Blinded core laboratories for FFR, FFR CT, and ICA CT: -Acquisition protocols according to societal guidelines 1 -Image quality independently evaluated using a predefined scoring system 2 -Site-read stenosis severity >50% 3 ICA: -Core-lab read stenosis severity >50% FFR: At maximum hyperemia during ICA Adenosine 140 180 micg/kg/min IV Positive: 0.80 4 0.80 4 1 Abbara S et al. JCCT 2009 2 Nørgaard B et al. JCCT 2013 3 Raff GL et al. JCCT 2009 4 Tonino PA et al. NEJM 2009

FFR CT : Clinical studies, NXT trial, Patient enrollment Screened Cohort (n=357) Study enrollment 9/2012 8/2013 10 sites in Europe, Asia, and Australia Image artifacts (n=44, 13%) Failed inclusion criteria (n=27) Excluded FFR quality (n=22): Invalid FFR (n=8), FFR in vessel <2 mm (n=11), missing measure location (n=3) Other (n=10) Secondary endpoints Patients n=254 Vessels n=484 Excluded from Primary Endpoint No ccta stenosis 30%-90% (n=3) Primary Endpoint Patients n=251

FFR CT : Clinical studies, NXT trial, Patients and CT characteristics CT Characteristics Nitrates 99.6% Patient Characteristics Age (years) [mean + SD] 64 ± 10 Male gender 64% Prior MI 2% Diabetes mellitus 23% Hypertension 69% Pre-test Likelihood of CAD 58% FFR 0.80 32% FFR assigned a value of 0.50 in 16 occluded vessels 3% Beta Blockers 78% Heart Rate (bpm) 63 Range 37-110 Prospective 54% mean dose (msv) 3 Retrospective 46% mean dose (msv) 14 Calcium score* Mean 302 Range 0 3599 >300 33% *Available for 214 patients

FFR CT : Clinical studies, NXT trial, Per-vessel FFR - FFR CT correlation Pearson s CC = 0.82, P<0.0001

Sensitivity FFR CT : Clinical studies, NXT trial, Discrimination of ischemia Per-patient Per-Vessel (n=484) Per-Patient Per-vessel (n=251) 1 - Specificity N=252 *Area under the receiver operating characteristics curve

FFR CT : Clinical studies, NXT trial, Per-patient diagnostic performance % 100 90 80 70 60 50 40 30 20 10 0 95% N=254 CI 92 86 81 79 65 Accuracy Specificity PPV Sensitivity NPV FFR CT < 0.80

FFR CT : Clinical studies, NXT trial, Per-patient diagnostic performance % 100 90 80 70 60 50 40 30 20 10 0 95% N=254 CI * * 81 79 64 53 51 46 40 34 65 94 91 92 93 Accuracy Specificity PPV Sensitivity NPV * 86 92 CT > 50% ICA > 50% FFR CT < 0.80 * p<0.0001

FFR CT : Clinical studies, NXT trial, Per-patient diagnostic performance % 100 90 80 70 60 50 40 30 20 10 0 95% N=254 CI * * 81 79 64 53 51 46 40 34 65 94 91 92 93 Accuracy Specificity PPV Sensitivity NPV * 86 92 CT > 50% ICA > 50% FFR CT < 0.80 * p<0.0001

FFR CT : Clinical studies, NXT trial, Per-patient diagnostic performance % 100 90 20 10 0 95% N=254 CI * * 81 79 94 91 92 93 80 * 70 64 65 60 53 51 50 FFR 46 40 40 CT correctly reclassified 68% of 34 CT false positive to true negatives 30 Accuracy Specificity PPV Sensitivity NPV 86 92 CT > 50% ICA > 50% FFR CT < 0.80 * p<0.0001

FFR CT : Clinical studies, NXT trial, Per-patient diagnostic performance LAD stenosis 70-90% FFR CT 0.93 FFR 0.94 FFR CT Model

FFR CT : Clinical studies, NXT trial, Per-vessel diagnostic performance % 100 90 80 70 60 50 40 30 20 10 0 N=484 95% C * * 86 86 71 65 66 * 60 40 33 61 83 84 84 92 94 Accuracy Specificity PPV Sensitivity NPV 95 CT > 50% ICA > 50% FFR CT < 0.80 * p<0.0001

FFR CT : Clinical studies, NXT trial, Intermediate lesions (30%-70%) 100 90 80 70 60 50 % 51 * * 80 79 * 63 93 91 85 92 ccta >50% FFR CT <0.80 *p<0.05 40 30 32 37 20 10 0 Acc Spec PPV Sens NPV n= 235 (93%)

FFR CT : Clinical studies, NXT trial, Coronary calcification 100 90 80 70 60 50 40 30 20 10 0 85 87 83 85 86 82 75 77 73 Acc Sens Spec Acc Sens Spec Acc Sens Spec FFR CT <0.80 Agatston score: mean, 302 range, 0-3599 Ag: 0 1-300 >300 N (214): 27 117 70

FFR CT : Clinical studies, NXT trial, Coronary calcification 100 90 80 70 * * * * * * FFR CT <0.80 ccta >50% *p<0.05 60 50 40 Agatston score: mean, 302 range, 0-3599 30 20 10 0 Acc Sens Spec Acc Sens Spec Acc Sens Spec Ag: 0 1-300 >300 N (214): 27 117 70

FFR CT : Clinical studies, DISCOVER-FLOW, DeFACTO, and NXT trials FFR CT has high diagnostic accuracy and discrimination for the diagnosis of ischemia

FFR CT : Clinical studies, DISCOVER-FLOW, DeFACTO, and NXT trials FFR CT has high diagnostic accuracy and discrimination for the diagnosis of ischemia When compared to anatomic interpretation by coronary CTA or invasive angiography, FFR CT leads to a marked increase in diagnostic accuracy, specificity, and PPV

FFR CT : Clinical studies, DISCOVER-FLOW, DeFACTO, and NXT trials FFR CT has high diagnostic accuracy and discrimination for the diagnosis of ischemia When compared to anatomic interpretation by coronary CTA or invasive angiography, FFR CT leads to a marked increase in diagnostic accuracy, specificity, and PPV FFR CT is performed from standard acquired CT datasets without the need for additional imaging, radiation or medication

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities Desai RR, AJR 2013

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities Per patient pooled sens / spec: 89% (95% CI, 84-93) / 85% (77-91) Per-territory pooled sens / spec: 88% (84-91) / 89% (87-90) Desai RR, AJR 2013

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities Single-center studies Desai RR, AJR 2013

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities Single-center studies # patients: 28-120 Desai RR, AJR 2013

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities Single-center studies # patients: 28-120 Local FFR reads Desai RR, AJR 2013

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities Single-center studies # patients: 28-120 Local FFR reads The rate of actual FFR measurements was <70% in 10 of 12 studies (ICA stenosis >90% => FFR, 0.50, and in normal vessels => FFR, 0.95) Desai RR, AJR 2013

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities Single-center studies # patients: 28-120 Local FFR reads The rate of actual FFR measurements was <70% in 10 of 12 studies (ICA stenosis >90% => FFR, 0.50, and in normal vessels => FFR, 0.95) Desai RR, AJR 2013

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities 22%-69% of FFR values were directly measured Desai RR, AJR 2013

FFR CT : Clinical studies, FFRct vs other non-invasive testing modalities 22%-69% of FFR values were directly measured All FFR values were directly measured Desai RR, AJR 2013

Diagnostic performance of Coronary diagnostic tests for Functional (FFR 0.80) disease

Diagnostic performance of Coronary diagnostic tests for Functional (FFR 0.80) disease

FFR CT : Clinical studies, Building the Body of Evidence 609 patients 1051 vessels, FFR directly measured in 1035 vessels (98%) DISCOVER-FLOW NXT DeFACTO Cath lab Population Dx Accuracy 30-90% Stenosis Dx Accuracy 2012 2013 2014 2015 59

Use of FFR CT to select patients for ICA and PCI may result in 30% lower costs and 12% fewer events at one year compared to the most common strategy of ICA 60

FFR CT : Clinical studies, Building the Body of Evidence 609 patients 1051 vessels, FFR directly measured in 1035 vessels (98%) DISCOVER-FLOW DeFACTO NXT PLATFORM Randomized Controlled Trials Analysis of existing databases Cath lab Population Dx Accuracy 30-90% Stenosis Dx Accuracy Stable Angina Outcomes and resources ACS (- enzyme) Outcomes and resources 2012 2013 2014 2015 61

Thank you for the attention

FFR CT false-negatives and FFR grey zone 24 vessels had false negative results of FFR CT when compared to FFR. FRR 0.75-0.80 ( grey zone ), n=17

FFR CT false-negatives and FFR grey zone 24 vessels had false negative results of FFR CT when compared to FFR. FRR 0.75-0.80 ( grey zone ), n=17 Assuming, patients with false-negative FFR CT values in the grey zone are in fact true negatives, the NPV for FFR CT increased to 98%. Thus, in vessels with FFR CT >0.80 the risk of having an FFR <0.75 is only 2%.

Limitations No control over CT image acquisition protocol at clinical sites Did not interrogate every vessel with invasive FFR Did not solely enroll patients with intermediate stenosis Did not test whether FFR CT -based revascularization reduces ischemia

Conclusions FFR CT demonstrated improved accuracy over CT for diagnosis of patients and vessels with ischemia FFR CT diagnostic accuracy 73% (95% CI 67-78%) Pre-specified primary endpoint >70% lower bound of 95% CI Increased discriminatory power FFR CT superior to CT for intermediate stenoses FFR CT computed without additional radiation or imaging First large-scale demonstration of patient-specific computational models to calculate physiologic pressure and velocity fields from CT images Proof of feasibility of FFR CT for diagnosis of lesion-specific ischemia